T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
HemaSphere | October 10, 2022 | Volume: 6 | Issue: No issue available | Pages: 46-47
10.1097/01.hs9.0000890968.53519.f4